Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$1.21MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marino Garcia
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 0.08
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 83.06
Financials
Revenue
$1.21M+3.2%Net Income
$-46.64MEBITDA
$-46.53MFree Cash Flow
$-50.70MEPS (diluted)
$-0.81Shares Outstanding (diluted)
57.34M+2493.9%Operating Expenses
$59.68MCash & Debt
$837.78MReturn of Capital
$0.00Revenue by Segment (annual)
$2.04MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.04M | $-162.34M | $-4.20 |
| 2024 | $6.24M | $-84.97M | $-2.55 |
| 2023 | $2.83M | $-43.55M | $-8.45 |
| 2022 | $6.42M | $-28.48M | $-7.60 |
| 2021 | $1.48M | $-13.11M | $-3.82 |
| 2020 | $0.00 | $-74.94M | $-27.30 |
| 2019 | $0.00 | $-76.77M | $-33.18 |
| 2018 | $0.00 | $-57.52M | $-27.62 |
| 2017 | $0.00 | $-35.49M | $-16.05 |
| 2016 | $0.00 | $-9.43M | $-4.27 |
Valuation
DNTHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-57.58%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·6d ago·Positive
Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newszacks.com·18d ago·Neutral
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.97 per share a year ago.
View source ↗ - Newsglobenewswire.com·40d ago·Positive
…tics Recognized Among Fortune's 2026 Best Workplaces In BioPharma NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced it was selected by Great Place To Work® and Fortune magazine for the 2026 Fortune Best Workplaces in BioPharma™ List. This is Dianthus' inaugural appearance on the …
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
…prubart Data Presentations Planned for 2026 AANEM Annual Meeting NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meet…
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - News (RSS)seekingalpha·77d ago·Neutral
Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement
View source ↗ - News (RSS)yahoo·78d ago·Negative
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
View source ↗ - News (RSS)seekingalpha·89d ago·Positive
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
View source ↗ - Newsseekingalpha.com·89d ago·Positive
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting multiple late-stage programs and reducing funding event risk through 2030. Claseprubart's dosing convenience, pathway selectivity, and strong early data set it apart amid evolving competitive dynamics, especially after Sanofi's setback.
View source ↗ - News (RSS)investing·100d ago·Neutral
Dianthus Therapeutics stock hits 52-week high at 114.64 USD
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $-0.96 per share
Typical surprise -2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.81 vs $-0.94beat
- Tue, Aug 4$-0.90 vs $-0.85miss
- Tue, May 5$-0.85 vs $-1.17beat
- Mon, Mar 9$-1.43 vs $-0.98miss
- Wed, Nov 5$-0.97 vs $-0.86miss
- Thu, Aug 7$-0.88 vs $-0.86miss
Estimates and results for DNTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DNTH officers and directors.
- Bought
- —
- Sold
- $43.4m
0 trades
45 trades
- Savitz Ryansold
- Savitz Ryansold
- Savitz Ryansold
- Savitz Ryansold
- Savitz Ryansold
- Savitz Ryansold
- Savitz Ryansold
- Savitz Ryansold
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DNTH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
